Venetoclax, a potent and selective BCL2 inhibitor, combined with tamoxifen had a tolerable safety profile and significant activity in patients with ER+/HER2− advanced BC that overexpresses BCL2 in a phase I clinical trial [135]. Here, ESR1 is linked to breast cancer.